Mr Hogg, aged 54, has been the Chief Executive Officer and an Executive Director of the Company since 2006. He is also a member of the Nomination Committee and Technical Committee of the Company. He joined the business in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of the Company’s strategy, business and listings. This includes the establishment of the Innovation Platform, Hutchison MediPharma, which now comprises nine drug candidates that are being investigated in clinical studies around the world and a scientific team of about 550 people. Furthermore, Mr Hogg oversaw the acquisition and operational integration of assets led to the formation of the Company’s Commercial Platform, which manufactures, markets and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.
Prior to joining the Company, Mr Hogg spent ten years with P&G, starting in the United States in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr Hogg then moved to China to manage P&G’s detergent business, followed by a move to Brussels to run P&G’s global bleach business.
Mr Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and a Master in Business Administration from the University of Tennessee.
Mr. Cheng has been an Executive Director since 2011 and our Chief Financial Officer since 2008. He is also a member of our nomination committee.
Prior to joining our Company, Mr. Cheng was vice president, finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008.
Mr. Cheng started his career as an auditor with Price Waterhouse (currently PricewaterhouseCoopers) in Australia in 1989. In 1995, he joined KPMG in Beijing before spending eight years with Nestlé in China where he was in charge of a number of finance and control functions in various operations. Mr. Cheng received a Bachelor of Economics from the University of Adelaide in 1988 and has been a member of the Chartered Accountants Australia and New Zealand since 1992.
Dr. Su has been an Executive Director of the Company since 2017 and has been our chief scientific officer since 2012. He is also a member of our nomination committee and technical committee. Dr. Su has headed all drug discovery and research since he joined our Company, including master-minding the Company’s scientific strategy, being a key leader of the Innovation Platform, and responsible for the discovery of each and every small molecule drug candidate in our pipeline. Prior to joining the Group in 2005, Dr. Su worked with Pfizer's U.S. research and development organization.
In 2017, he was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most Influential Drug R&D Leaders in China.
Dr. Su received a Bachelor of Science degree in Chemistry from Fudan University in Shanghai in 1982 and completed a Ph.D. and Post-Doctoral Fellowship in Chemistry at Harvard University in 1988 under the guidance of Nobel Laureate Professor E. J. Corey.
Dr. Zhou joined Shanghai Hutchison Pharmaceuticals in 2001.
Prior to this, Dr. Zhou worked for Sanofi Synthélabo for over ten years rising from a Sales Representative to National Sales Director for China. Dr. Zhou holds an MBA from China Europe International Business School (CEIBS) and a Master's degree in Medicine from Xian Medical University, China.
Dr. Wu heads all non-clinical development at the company, focusing on the CMC development and manufacturing of the Company’s pipeline. The Pharmaceutical Sciences department is responsible for process research, API & drug product manufacture, analytical R&D, quality control, supply chain management, CMC regulatory affairs, pilot plant development, and managing third party contractors. Dr Wu has over 22 years of experience in drug discovery and development.
Prior to joining Chi-Med in 2008, Dr Wu held several leadership positions, including Senior Director of Pharmaceutical Sciences at Phenomix, a California biotech company; Director of Pharmaceutical Development at Pfizer Global R&D in San Diego (formerly Agouron); and group leader at Roche in Palo Alto. Dr. Wu has led many teams and advanced numerous candidates through different phases of clinical development and commercialization, such as the blockbuster anti-cancer drug Sutent.
Dr. Wu received a Ph. D. degree from Hong Kong University, and an MBA degree from the University of California at Irvine. He is the past Chairman and President of the Board of the Sino-American Biotechnology and Pharmaceutical Association. He received a Dean’s Scholar Award from the University of California at Irvine, a Leadership Award from the Sino-American Biotechnology and Pharmaceutical Association, and an American Heart Association Fellowship.
Mr. Lee focuses on Chi-Med's strategic management, corporate operations, investor relations and supporting its numerous R&D alliances. This includes leading or assisting with the project management of certain clinical programmes, coordination of R&D leadership, and R&D financial management.
Prior to joining the company in 2009, Mr. Lee was with Credit Suisse in the United States and Europe, where he was involved in the execution and origination of mergers, acquisitions, public and private financings, and corporate strategy for pharmaceutical, life science and healthcare companies such as AstraZeneca, Bristol-Myers Squibb, Genzyme and Syngenta, amongst others.
Mr. Lee received his Bachelor of Engineering in Biochemical Engineering with First Class Honours from University College London, where he was awarded a Dean’s Commendation. He also received a Master of Business Administration from the Massachusetts Institute of Technology, Sloan School of Management.
Dr. Wang heads all alliance management and business development for the company. She has been instrumental in engaging with, negotiating, executing and very actively liaising with all our development partners, including AstraZeneca, Nestlé Health Science, and Eli Lilly.
Prior to joining Chi-Med in 2010, Dr. Wang spent 16 years with Eli Lilly and was the Head for Asian Biology Research, responsible for establishing and managing research collaborations in China and Pan-Asia. Dr. Wang has broad drug discovery and development experience spanning several therapeutic areas including infectious diseases, inflammation and oncology. She was a co-inventor for several drug candidates including the blockbuster drug INCIVEK (telaprevir, LY570310) launched in 2011 for treatment of HCV infection.
Dr. Wang has numerous patents, published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. She received her Ph.D. in Biology from Purdue University, USA.
Mr. Chen holds and has held several key senior management roles at Chi-Med, spearheading many of our businesses within our Commercial Platform. When he initially joined Chi-Med he was the Deputy General Manager of Hutchison Baiyunshan, overseeing the manufacture, marketing and distribution of our proprietary OTC drug products. In 2012, he assumed the parallel role of General Manager of Hutchison Healthcare, which focuses on health supplements. In 2014, he stepped down from Hutchison Baiyunshan to become the General Manager of the newly-formed Hutchison Sinopharm business, focusing on providing marketing, distribution and logistics services for prescription drugs manufactured by third parties.
In 2018, Mr. Chen was promoted to the role of Chi-Med - Chief Commercial Officer - China, and will be responsible for the establishment of both government affairs and commercial organizations within our Innovation Platform. He will retain his current responsibilities for Hutchison Sinopharm and Hutchison Healthcare.
Prior to joining Chi-Med in 2011, Mr. Chen spent twelve years with Bristol-Myers Squibb starting from a Product Manager and becoming its National Sales & Marketing Director in China.
Mr. Chen received a Bachelor's degree in Medicine from Nanjing Medical University, China and an EMBA from Cheung Kong Graduate School of Business.
Dr. Kania has led all strategic priorities and performance objectives for our international operations, including building a highly integrated cross-functional organization, centered on the dual aims of accelerating global ex-China approvals of our products; and realizing the full commercial value of those products globally. As Chief Medical Officer he leverages his significant experience and expertise in clinical development, including accelerating the clinical development of surufatinib and fruquintinib in the US and EU, and evolving the earlier stage programs.
Dr. Kania had spent 25 years with Lilly, leading teams on several oncology products, including Erbitux®, Alimta® and Gemzar®, around the world, with experience that includes clinical research and development; oncology product development; global medical affairs including product launches; and medical policy and strategy. Dr. Kania joined Lilly in 1993 after practicing as an anesthesiologist and critical care physician.
Dr. Kania is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Kania received his medical training at the Silesian School of Medicine in Katowice, Poland, and subsequently completed an anesthesiology and critical-care residency, with board certification from Jagiellonian University School of Medicine in Krakow. Dr. Kania also holds an MBA degree from The University of Chicago Booth Graduate School of Business.
Mr Held is responsible for establishing and leading our commercial presence in the U.S. and building the commercial infrastructure for our international operations, inclusive of launch strategy, marketing, sales, market access, and operational planning.
Mr Held has more than 30 years of experience in the pharmaceutical industry with a majority of time spent in the oncology commercial space. In his most recent assignment at Daiichi Sankyo, he served as Vice President of Daiichi Sankyo’s emergent Antibody Drug Conjugate strategic platform. Prior to this, he held commercial roles of increasing responsibility at Novartis Oncology, where he worked from 1997 to 2017, gaining invaluable experience in the solid tumor arena, including importantly neuroendocrine tumors.
Tom holds a BS in Economics from Allegheny College and an MBA from Ashland University.
Ms. Cui leads the Government Affairs department of our Company in China. She has over 20 years of experience and management expertise in China’s pharmaceutical industry. She held senior management positions within the Sinopharm Group and the Shanghai Pharmaceutical Group from 2002, the two largest pharmaceutical groups in China.
Prior to joining Chi-Med, she was the Vice President of Shanghai Shyndec Pharmaceutical Co., Ltd., which is the Chemical Pharmaceuticals platform of Sinopharm Group, where she was in charge of operations and strategy. Before that, she held various senior leadership positions including Board Chairman of Sino-American Shanghai Squibb Pharmaceuticals Co., Ltd. She was also the CEO of Shanghai Asia Pioneer Pharmaceutical Co., Ltd. and the Board Chairman of Shanghai New Asiatic Pharmaceutical Co., Ltd., both major companies of Shanghai Pharmaceutical Group.
In addition to her extensive experience in the pharmaceutical industry, Ms. Cui is a current member of the Shanghai Committee of the Chinese People's Political Consultative Conference. She also served as a deputy to the Shanghai Municipal People's Congress for 10 years.
Ms. Cui received a bachelor’s degree in Chemistry from Fudan University in 1987 and an EMBA from China Europe International Business School in 2003.
Mr. Nixon has been Group General Counsel of the Company since May 2015 and has worked with the Company since 2006.
Prior to joining the Company, Mr. Nixon was Group Senior Legal Counsel for Hutchison Whampoa in both Hong Kong and London and prior to that Senior Legal Counsel for Three UK the mobile phone operator. Mr. Nixon has been with the CK Hutchison Group since 2001.
Mr. Nixon received an LL.B (Hons) from Middlesex University and is a qualified solicitor in England & Wales with over 26 years of experience.
Mr. Walter leads the strategy and management of the Company’s Consumer Products Division, focusing on Health & Beauty products in Asia.
Prior to joining in 2009, Mr. Walter spent seven years with the Henkel Group in Germany managing a global Hair Care portfolio with responsibilities to grow sales and profitability through marketing and innovation. Before that he held legal and corporate functions within Henkel dealing with intellectual property, licensing and M&A. Mr. Walter started his career as a Corporate and IP lawyer with Arthur Andersen in Germany.
Mr. Walter holds a law degree from the University of Cologne in Germany and an MBA from Kellogg Northwestern School of Management & WHU, USA. He is also a member of the Bar in Dusseldorf, Germany.
Mr. Shih joined Chi-Med in 2019 and he focuses on providing overall strategic HR and Organization Development solutions including Talent Acquisition, Development, Retention, Succession Planning, Performance Management at all levels, functions, and business units across the company. His role is aimed at helping company to integrate the right structure, culture, talent, leadership, and organization platforms necessary to take Chi-Med to the next level of innovative biopharma over the coming years.
Prior to joining us, Mr. Shih spent 16 years with MSD (Merck & Co. in the US) , with the last position as the Regional Director of Oncology HRBP for Japan, China, & AP in which he helped to grow MSD Oncology business (Keytruda®) both for commercial and medical organizations in 14 markets. He also held substantial global talent development roles and legacy in developing senior leaders in the organization. Mr. Shih was also a senior manager at Accenture and DDI where his practices in delivering major enterprise transformation with human capital solutions, he started his career at American Express and was also an investment analyst in UK.
Mr. Shih holds a Diploma in Industrial Engineering. He also received an MBA in Strategy Management from Strathclyde Graduate Business School in UK.
Mr. Magnanelli had spent about 20 years in the pharmaceutical industry, including over 12 years with Gilead Sciences in management and commercial roles involved in the launch of the hepatitis franchise in Japan; and the establishment of new operations in mainland China, Hong Kong, South Korea, Taiwan, Austria, BeNeLux, Israel, the Nordic Region, Poland, and Switzerland.
Mr. Magnanelli received his degree in Economics from the University of Genova and his Masters of Business Administration from the MIB School of Management.
Mr. Leung has spent two decades in investment projects in China, across different places and industries. At Chi-Med he has been involved in structuring and managing direct investment projects, particularly the Hutchison Baiyunshan joint venture. He was one of the leading team members in its establishment and has provided continuous support for its operations, including most recently as its Executive Deputy General Manager.
Prior to joining Hutchison China in 2000, Mr. Leung spent seven years with Hopewell Holdings Limited, focusing on investing, building and operating infrastructure projects in China, including toll roads and power plants. Michael gained extensive China experience through the daily operation of these projects and successfully helped these sino-foreign joint ventures to gain access to funding from foreign banks and overseas investors.
Mr. Leung holds a First Class Honours degree in Business Administration from Simon Fraser University, Canada and received his MBA from the University of British Columbia, Canada.